REDWOOD CITY, Calif., June 10, 2026 /PRNewswire/ -- Zilliz, the company behind Milvus, the world's most widely adopted ...
Demand for adeno-associated viral (AAV) vectors is increasing as more and more cell and gene therapy firms use them to make products. In response, vector suppliers are embracing faster, more efficient ...
The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results